In this article, we will look at the 15 Best Long Term Low Volatility Stocks to Invest In.
On January 26, Sherry Paul, Morgan Stanley senior portfolio manager, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and whether more volatility is expected ahead.
According to her, one of the most important things that came out of Davos was going from the phrase globalization to the “new world order”, in which the former felt more like a conscious uncoupling, while the latter has a much harsher tone to it. This translates to the fact that the urgency around reimagining supply chains, partnerships, and the advancement of AI and automation manufacturing in the United States, along with the dollar that is now lower, becomes even higher.
READ ALSO: 10 Best Undervalued Stocks to Buy Under $10 and 10 Best Strong Buy Stocks to Invest In Under $5.
Paul added that this means there is increased volatility ahead, especially as these trends unfold further. However, she also stated that it is important to remember volatility as a part of investing, and that doesn’t necessarily mean that something bad is taking place. According to her, volatility means that something more emergent is happening, and the emergence is moving away from the Mag 7 into what she calls the “magnificent thematics”. If one follows these thematics of the new world order of AI, automation, longevity, innovation, and a couple of others, one can start trailing down into the different sector weightings that people should not be overweighting in, and not necessarily moving into cash.
With these trends in view, let’s look at the best long term low volatility stocks to invest in.
Our Methodology
We sifted through financial media reports and ETFs tracking blue chip and high quality stocks to find the best long term stocks with stable fundamentals and a beta below 1. We then chose the top 15 with the highest number of hedge fund holders, as of Q3 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.
Note: All data was recorded on January 30.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
15 Best Long Term Low Volatility Stocks to Invest In
15. AstraZeneca PLC (NASDAQ:AZN)
Number of Hedge Fund Holders: 54
AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) announced on January 30 that it is bolstering its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals for the advancement of several next-generation therapies for obesity and type 2 diabetes across eight programmes.
The agreement entails the initial progress of four programmes by the companies, leveraging CSPC’s advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology. AstraZeneca PLC (NASDAQ:AZN) reported that it would receive exclusive global rights outside of China to CSPC’s once-monthly injectable weight management portfolio, which includes one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, and three preclinical programmes with differing mechanisms designed to offer extended therapeutic benefits for people living with obesity and weight-related conditions.
Management further stated that the collaboration complements the company’s existing weight management portfolio, which encompasses an expanding pipeline of next-generation treatments addressing the complexities of obesity and weight-related complications, pursuing multiple modalities and pathways to specialize treatment based on individual needs. This includes elecoglipron (formerly AZD5004), a small molecule oral GLP1RA, AZD9550, a weekly injectable dual GLP-1/glucagon receptor agonist, and AZD6234, a weekly injectable selective amylin receptor agonist (SARA), along with several preclinical assets.
AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.
14. International Business Machines Corporation (NYSE:IBM)
Number of Hedge Fund Holders: 66
International Business Machines Corporation (NYSE:IBM) is one of the best long term low volatility stocks to invest in. Argus lifted the price target on International Business Machines Corporation (NYSE:IBM) to $360 from $340 on January 30, reaffirming a Buy rating on the stock and citing its better-than-anticipated Q4, led by GenAI and hybrid cloud momentum, along with the z17 mainframe. The firm also noted the company’s acquisition of HashiCorp, stating that it brings improved infrastructure and security automation to International Business Machines Corporation’s (NYSE:IBM) hybrid cloud and AI solutions.
International Business Machines Corporation (NYSE:IBM) also received a rating update from RBC Capital on January 29, which lifted the price target on the stock to $361 from $350 and maintained an Outperform rating. The firm told investors that the company delivered a solid end to 2025, delivering a balance of stability and execution in the form of free cash flow outperformance with exposure to secular themes. It added that the strength of the z17 refresh cycle, along with upside from software with a particularly strong data segment, drove revenue upside.
International Business Machines Corporation (NYSE:IBM) is an IT company that provides integrated solutions leveraging information technology and the knowledge of business processes. Its operations are divided into the following segments: Software, Consulting, Infrastructure, Financing, and Other.
13. Cisco Systems, Inc. (NASDAQ:CSCO)
Number of Hedge Fund Holders: 74
Cisco Systems, Inc. (NASDAQ:CSCO) is one of the best long term low volatility stocks to invest in. Cisco Systems, Inc. (NASDAQ:CSCO) received a rating update from Evercore ISI on January 26, which upgraded the stock to Outperform from In Line and raised the price target to $100 from $80.
The firm stated that while investors will debate whether the stock is secular or cyclical, Evercore ISI sees “plenty of tailwinds” that support Cisco Systems, Inc.’s (NASDAQ:CSCO) ability to sustain high single-digit sales and low-teens EPS growth on a multi-year basis. This includes AI momentum, a campus refresh, EBIT margin expansion, and the recovery in traditional enterprise and telco markets. The firm further told investors that an EPS greater than $5.00 is possible by FY27 with a resurgence in core networking coupled with AI acceleration.
The rating update came the same day Cisco Systems, Inc. (NASDAQ:CSCO) announced the launch of the Cisco 360 Partner Program after fifteen months of co-design with partners. Now live, the program is specialized to deliver outcomes that are achievable only through Cisco and its ecosystem, highlighting the power of partnering with Cisco in the AI era.
Management reported that the Cisco 360 Partner Program provides additional clarity and empowers partners to drive more predictable profitability, while the new Cisco Partner Locator tool allows customers to search for the right partner across key Cisco portfolios, such as Networking, Splunk, Collaboration, Security, Services, and Cloud and AI Infrastructure.
Cisco Systems, Inc. (NASDAQ:CSCO) is involved in the manufacture, design, and sale of Internet Protocol-based networking products and services associated with the communications and IT industry. The company’s operations are divided into the following geographical segments: the Americas, EMEA, and APJC, and its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products.
12. RTX Corporation (NYSE:RTX)
Number of Hedge Fund Holders: 76
RTX Corporation (NYSE:RTX) is one of the best long term low volatility stocks to invest in. RTX Corporation (NYSE:RTX) announced its 2025 results and 2026 outlook on January 27, reporting sales of $24.2 billion for fiscal Q4 2025, up 12% compared to the prior year and up 14% organically. Sales for the full year 2025 reached $88.6 billion, up 10% versus last year and up 11% organically. The company’s outlook for the full year 2026 entails adjusted sales of $92.0 to $93.0 billion, and organic sales growth of 5%-6%.
RTX Corporation (NYSE:RTX) received several rating updates following the earnings release. Most recently, Bernstein lifted the price target on the stock to $204 from $189 on January 29 while maintaining a Market Perform rating on the shares. The firm stated that RTX Corporation (NYSE:RTX) beat consensus EPS and revenues in its fiscal Q4 2025 results, with Q4 2025 adjusted EPS reaching $1.55, above consensus $1.47. It added that adjusted revenue of $24.24 billion was above the consensus of $22.63 billion, while revenues were above consensus in all segments.
RTX Corporation (NYSE:RTX) is an aerospace and defense company that provides aerospace and defense services and systems to military, commercial, and government customers. The company operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD).
11. The Procter & Gamble Company (NYSE:PG)
Number of Hedge Fund Holders: 87
The Procter & Gamble Company (NYSE:PG) is one of the best long term low volatility stocks to invest in. On January 27, Berenberg Bank reaffirmed a Hold rating on The Procter & Gamble Company (NYSE:PG) and set a price target of $156. The same day, TD Cowen downgraded the stock to a Hold from a Buy while raising the price target to $156 from $150.
The firm told investors that the pace of The Procter & Gamble Company’s (NYSE:PG) recovery is “likely to drag”, and that bulls own the shares on the assumption that the company’s organic sales growth bottomed in Q2 of 2025 at 0% and would recover on a recovery in market share. However, TD Cowen expects the company’s growth to “remain subdued” at 2% over the next two years, primarily due to pressure on the Hispanic consumer and a lack of pricing power.
The Procter & Gamble Company (NYSE:PG) released its fiscal Q2 2026 results on January 22, reporting net sales of $22.2 billion, up 1% compared to the prior year. Organic sales remained unchanged versus last year, and excluded the effects of foreign exchange and acquisitions and divestitures. Diluted net earnings per share were $1.78, reflecting a drop of 5% compared to the prior year, attributed primarily to incremental restructuring charges in the current year.
The Procter & Gamble Company (NYSE:PG) provides branded consumer packaged goods to consumers across the globe. Its operations are divided into Fabric & Home Care, Grooming, Beauty, Health Care, Feminine & Family Care, and Baby. The company boasts a strong portfolio of brands, which includes reputable names such as Head & Shoulders, Pantene, Old Spice, Olay, Herbal Essences, Safeguard, Tide, Always, Venus, Oral-B, Ariel, Crest, Tampax, and others.
10. Chevron Corporation (NYSE:CVX)
Number of Hedge Fund Holders: 89
Chevron Corporation (NYSE:CVX) is one of the best long term low volatility stocks to invest in. Chevron Corporation (NYSE:CVX) announced its fiscal Q4 2025 earnings on January 30, with reported earnings of $2.8 billion and adjusted earnings of $3.0 billion. Cash flow from operations for the quarter reached $10.8 billion, while adjusted free cash flow was $4.2 billion. Chevron Corporation (NYSE:CVX) also raised its 2025 worldwide and U.S. production by 12% and 16%, respectively, to record levels.
Management stated that the company delivered several milestones in the year, including successfully integrating Hess, delivering record production, and starting up major projects. Chevron Corporation (NYSE:CVX) delivered on its initial $1 billion synergy target after the integration of Hess, and its 50 percent-owned affiliate Tengizchevroil (TCO) started up the Future Growth Project in Kazakhstan. In addition, in the U.S., several notable projects attained first oil in the Gulf of America, and the Permian Basin delivered on its production target.
Chevron Corporation (NYSE:CVX) further reported that it continually advanced new energies opportunities in power, lithium, and hydrogen, attaining structural cost reductions of $1.5 billion in 2025. This allowed it to raise its production to record levels while generating the highest cash flow from operations in its history at similar commodity prices. The trends positioned Chevron Corporation (NYSE:CVX) to raise its annual dividend payout per share for the 39th consecutive year.
Chevron Corporation (NYSE:CVX) provides oil and gas energy solutions, including crude oil and natural gas, the manufacture of transportation fuels, petrochemicals, lubricants, and additives, and the development of technologies that boost business and the industry. Its operations are divided into the Upstream and Downstream segments.
9. Philip Morris International Inc. (NYSE:PM)
Number of Hedge Fund Holders: 90
Philip Morris International Inc. (NYSE:PM) is one of the best long term low volatility stocks to invest in. Philip Morris International Inc. (NYSE:PM) announced that its experts presented scientific evidence to the FDA’s Tobacco Products Scientific Advisory Committee on January 22 as part of the FDA’s process for a Modified Risk Tobacco Product designation for their ZYN nicotine pouch products. Management stated that the designation would allow Philip Morris International Inc.’s (NYSE:PM) U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that they may reduce their risk of smoking-related diseases by switching completely to ZYN. The company is also looking forward to a decision by the FDA.
The same day, Stifel Nicolaus reiterated a Buy rating on Philip Morris International Inc. (NYSE:PM) and set a price target of $180. In addition, Philip Morris International Inc. (NYSE:PM) received a rating update from Jefferies on January 20, with the firm downgrading the stock to Hold from a Buy and bringing the price target down to $180 from $220. The firm told investors that it sees limited re-rating potential for the shares in 2026, adding that the company’s competitor, British American Tobacco, is driving category growth in U.S. pouches while Japan Tobacco is “competing more assertively” in heated tobacco. Jefferies thus sees potential downside risk to the consensus estimate for Philip Morris International Inc. (NYSE:PM), supporting the downgrade.
Philip Morris International Inc. (NYSE:PM) is a holding company involved in delivering products to support a smoke-free future, including products outside of the nicotine and tobacco sector. The company’s operations are divided into the following geographical segments: Europe Region (Europe), South and Southeast Asia, Commonwealth of Independent States, Middle East, and Africa Region (SSEA, CIS, and MEA), East Asia, Australia, and PMI Duty Free Region (EA, AU, and PMI DF), and Americas Region (Americas).
8. Merck & Co., Inc. (NYSE:MRK)
Number of Hedge Fund Holders: 92
Merck & Co., Inc. (NYSE:MRK) is one of the best long term low volatility stocks to invest in. Merck & Co., Inc. (NYSE:MRK) announced on January 27 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q2 2026. Management reported that the payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026.
The same day, Merck & Co., Inc. (NYSE:MRK) received positive rating updates from Cantor Fitzgerald and Citi. Cantor lifted the price target on the stock to $116 from $83, maintaining a Neutral rating on the shares. The firm told investors that it anticipates near-term guidance to align with a below-consensus outlook, which may create a temporary overhang. It added that performance in 2026 should hinge on additional de-risking of the late-stage pipeline and incremental business development, areas that were behind much of the stock’s gains in 2025.
Citi also raised the price target on Merck & Co., Inc. (NYSE:MRK) to $115 from $110 on January 27, and maintained a Neutral rating while adjusting price targets in the biopharma group as part of a fiscal Q4 preview. The firm told investors that the group may have a favorable setup in 2026 due to estimates that are “beatable” and lower policy risk.
Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people. Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.
7. AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 93
AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to invest in. On January 27, Citi cut the price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while maintaining a Neutral rating on the shares. The firm told investors that it adjusted price targets in the biopharma group as part of a Q4 preview, adding that “beatable” estimates and reduced policy risk are expected to create a favorable setup for the group in 2026.
However, Berenberg Bank lifted the price target on AbbVie Inc. (NYSE:ABBV) to $275 from $270 on January 20, reiterating a Buy rating. It updated its forecasts for the company’s Skyrizi and Rinvoq, and cited an “exceptional” growth outlook as one of the primary reasons behind the optimistic rating.
In a separate development, AbbVie Inc. (NYSE:ABBV) announced on January 16 topline results from its Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab in comparison to the investigator’s choice of chemoimmunotherapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma. Epcoritamab is a T-cell-engaging bispecific antibody administered subcutaneously.
The study exhibited an improvement in progression-free survival, with improvements also observed in complete response rates, duration of response, and time to next treatment among patients treated with epcoritamab. AbbVie Inc. (NYSE:ABBV) further reported that the study did not demonstrate a statistically significant improvement in overall survival.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
6. Johnson & Johnson (NYSE:JNJ)
Number of Hedge Fund Holders: 103
Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher blended P/E multiple, which in turn assumes a raised MedTech multiple on a higher Pharma multiple and higher organic growth, given a defensive premium.
BofA added that a Daubert ruling in the talc MDL case may be issued in the upcoming 1-2 months. However, it stated that the outcome of any legal case is “inherently unpredictable”, and that includes any potential settlement or injunction. The firm believes the talc risk to be manageable, as even a mid-teens billion resolution cost is less than 3% of the company’s market cap.
In a separate development, Johnson & Johnson (NYSE:JNJ) announced on January 27 the FDA approval of DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone to treat adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. Regardless of transplant eligibility, D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients.
Management added that the FDA approval marks the twelfth indication for DARZALEX FASPRO® and fifth in the newly diagnosed setting, highlighting its significant role as a foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients.
Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, including oncology, infectious diseases, immunology, cardiovascular and metabolic diseases, and others. The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.
5. Walmart Inc. (NYSE:WMT)
Number of Hedge Fund Holders: 104
Walmart Inc. (NYSE:WMT) is one of the best long term low volatility stocks to invest in. On January 30, UBS lifted the price target on Walmart Inc. (NYSE:WMT) to $135 from $122 and maintained a Buy rating on the stock.
In a separate development, Walmart Inc. (NYSE:WMT) announced on January 28 that it is supporting its continuously expanding presence in the Health & Wellness domain by investing in pharmacy associates delivering care. The company elevated 3,000 roles to pharmacy operations team lead positions, paying an average of $28 an hour, with the potential to earn up to $42 an hour. Management clarified that pharmacy technicians make an average of $22 an hour and will be eligible to make more with increased pay ranges up to $40.50 an hour.
Reuters reported the same day that Walmart Inc.’s (NYSE:WMT) move is aimed at bolstering local pharmacy teams and expanding staffing across its 4,600 locations, as the company is in the process of strengthening its digital offerings, such as expanded pharmacy delivery, access to Eli Lilly’s LillyDirect program, and Better Care Services. No college degree is required to take on the role of a pharmacy sales associate, technician, or operations team lead, as Walmart Inc. (NYSE:WMT) pays for associates to become certified pharmacy technicians.
Reuters also provided additional perspective on the situation, stating that Walmart Inc.’s (NYSE:WMT) rival Amazon has also been expanding same-day prescription delivery to additional U.S. cities to push into the pharmacy market, and recently began offering Novo Nordisk’s new Wegovy weight‑loss pill through insurance plans.
Walmart Inc. (NYSE:WMT) is an omnichannel retailer operating retail and wholesale stores, clubs, e-commerce websites, and mobile applications. It offers an elaborate array of items, including food, beverages, general merchandise, electronics, and more.
4. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 114
Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device manufacturing facility, producing next-generation weight-loss therapies. These include retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple hormone receptor agonist. The investment decision marks the fourth new U.S. manufacturing site announced by Eli Lilly and Company (NYSE:LLY) since February 2025, and highlights its commitment to strengthening domestic medicine production.
Management reported that the facility would bring 850 high-value jobs to the region, including scientists, engineers, lab technicians, and operations personnel. Eli Lilly and Company (NYSE:LLY) expects construction on the site to begin in 2026, with the facility being operational in 2031.
Eli Lilly and Company (NYSE:LLY) reported that the Lehigh Valley site was chosen from over 300 applications, primarily due to its technical manufacturing economy, proximity to STEM universities, and its existing infrastructure. Management added that with the biotech industry experiencing increasing demand, the Pennsylvania region offers convenient access to transportation, utilities, and favorable zoning and incentives.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
3. Alibaba Group Holding Limited (NYSE:BABA)
Number of Hedge Fund Holders: 130
Alibaba Group Holding Limited (NYSE:BABA) is one of the best long term low volatility stocks to invest in. On January 29, China Merchants Securities reiterated a Buy rating on Alibaba Group Holding Limited (NYSE:BABA) and set a price target of HK$194.00. The rating update came the same day Reuters reported that Alibaba Group Holding Limited’s (NYSE:BABA) logistics arm, Cainiao, is set to buy stake in Chinese robovan developer Zelostech. The Wall Street Journal, which originally announced the news, reported that the deal would create a business valued at around $2 billion.
Reuters further reported that according to Zelostech, “Cainiao will not become a controlling shareholder of Zelostech”, and that Cainiao will “contribute its autonomous-driving business” to the deal and make a cash investment in the company. An emailed statement from Zelostech, according to Reuters, further stated that “Zelostech and Cainiao’s autonomous-driving unit have entered into a deep strategic integration, jointly building a RoboVan Super Carrier in the unmanned freight sector.”
The Journal reported that Cainiao’s autonomous-driving unit would be folded into Zelostech, and that the latter would operate both brands simultaneously.
Alibaba Group Holding Limited (NYSE:BABA) manages and provides technology infrastructure and marketing platforms. It operates through seven segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments.
2. Mastercard Incorporated (NYSE:MA)
Number of Hedge Fund Holders: 136
Mastercard Incorporated (NYSE:MA) is one of the best long term low volatility stocks to invest in. Mastercard Incorporated (NYSE:MA) has received several rating updates after its fiscal Q4 and full year 2025 earnings release on January 29, in which it reported strong results with net revenue up 16% year-over-year or 15% on a currency-neutral basis.
Following the release, TD Cowen lifted the price target on Mastercard Incorporated (NYSE:MA) to $671 from $668 on January 30, maintaining a Buy rating on the stock and stating that the company delivered a strong fiscal Q4 2025 with solid top-line growth. The positive trends were supported by a solid organic VASS momentum and a stable consumer.
In addition to TD Cowen, Morgan Stanley also lifted the price target on the stock to $678 from $665 the same day, maintaining an Overweight rating on the shares. The firm stated in a post-earnings note that Mastercard Incorporated (NYSE:MA) called out a renewal of its credit partnership with Capital One, and also said that it would be the network for a substantial portion of Capital One’s newly acquired credit accounts. Morgan Stanley believes that the renewal reinforces the considerable performance advantage of this network, and is also encouraged by the healthy underlying domestic and cross-border spend trends.
Mastercard Incorporated (NYSE:MA) is a technology company that provides payment solutions for developing and implementing debit, credit, prepaid, commercial, and payment programs via its brands. Its portfolio includes Mastercard, Cirrus, and Maestro. The company also offers intelligence and cyber solutions.
1. Visa Inc. (NYSE:V)
Number of Hedge Fund Holders: 179
Visa Inc. (NYSE:V) is one of the best long term low volatility stocks to invest in. On January 31, Macquarie reiterated a Buy rating on Visa Inc. (NYSE:V) and set a price target of $410.00. The rating update came after Visa Inc. (NYSE:V) reported its fiscal Q1 2026 earnings on January 29, reporting $10.9 billion in net revenue for the quarter, up 15%, or 13% on a constant-dollar basis. Management attributed the growth to year-over-year growth in payments volume, cross-border volume, and processed transactions.
GAAP net income for fiscal Q1 2026 was $5.9 billion or $3.03 per share, reflecting a growth of 14% and 17%, respectively, over the prior year’s results. Visa Inc. (NYSE:V) further reported that payment volume for the three months ended September 30, 2025, rose 9% over the prior year on a constant-dollar basis, adding that the fiscal first quarter service revenue is recognized on it. Furthermore, payment volume for the three months ended December 31, 2025 reflected an 8% growth compared to the prior year on a constant-dollar basis. Fiscal first quarter service revenue also exhibited positive trends, rising 13% over the prior year to $4.8 billion, recognized based on payment volume in the prior quarter.
Visa Inc. (NYSE:V) provides digital payment services. It offers credit cards, debit cards, prepaid products, global automated teller machines, and commercial payment solutions.
While we acknowledge the potential of V to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than V and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
